Summary of Immunophenotype of the Specific Lymphoma Types With CD56 Expression
Case No. . | Diagnosis . | CD2 . | CD3/Leu4 . | CD3ε . | CD4 . | CD5 . | CD7 . | CD8 . | CD16 . | CD57 . | CD68 . | TCR . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
42 | S-100 protein-positive T-cell lymphoma | + | + | + | + | + | − | − | + | − | ND | βF1+ |
43 | T-cell small lymphocytic lymphoma/chronic lymphocytic leukemia | + | + | + | + | + | − | + | − | − | ND | βF1+ |
44 | T-cell prolymphocytic leukemia/lymphoma | + | − | + | − | − | + | + | + | + | ND | ND |
45 | Hepatosplenic γδ T-cell lymphoma | + | + | + | − | + | + | − | − | − | ND | βF1− |
TCRδ1+ | ||||||||||||
46 | T-lymphoblastic lymphoma3-150 | + | − | + | − | + | + | − | − | − | − | ND |
47 | B-lymphoblastic lymphoma3-150 | − | − | − | − | − | − | − | − | − | ND | ND |
48 | True histiocytic lymphoma | − | − | − | + | − | − | − | − | − | + | ND |
49 | True histiocytic lymphoma | − | − | − | + | − | − | − | − | − | + | ND |
Case No. . | Diagnosis . | CD2 . | CD3/Leu4 . | CD3ε . | CD4 . | CD5 . | CD7 . | CD8 . | CD16 . | CD57 . | CD68 . | TCR . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
42 | S-100 protein-positive T-cell lymphoma | + | + | + | + | + | − | − | + | − | ND | βF1+ |
43 | T-cell small lymphocytic lymphoma/chronic lymphocytic leukemia | + | + | + | + | + | − | + | − | − | ND | βF1+ |
44 | T-cell prolymphocytic leukemia/lymphoma | + | − | + | − | − | + | + | + | + | ND | ND |
45 | Hepatosplenic γδ T-cell lymphoma | + | + | + | − | + | + | − | − | − | ND | βF1− |
TCRδ1+ | ||||||||||||
46 | T-lymphoblastic lymphoma3-150 | + | − | + | − | + | + | − | − | − | − | ND |
47 | B-lymphoblastic lymphoma3-150 | − | − | − | − | − | − | − | − | − | ND | ND |
48 | True histiocytic lymphoma | − | − | − | + | − | − | − | − | − | + | ND |
49 | True histiocytic lymphoma | − | − | − | + | − | − | − | − | − | + | ND |
CD3ε immunoreactivity is demonstrated on paraffin section.
Abbreviation: ND, not determined.
Both cases of lymphoblastic lymphoma show TdT immunoreactivity.